Arcus Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Arcus Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $247.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $258.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $117.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $112.00M | Feb 25, 2025 |
| FY2020 | Dec 31, 2020 | $9.49M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $64.53M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $1.75M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $1.75M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $9.75M | Feb 25, 2021 |
| FY2020 | Sep 30, 2019 | $1.75M | Feb 25, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $51.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $37.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $38.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $383.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $78.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $15.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $8.35M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($353.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($283.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($307.00M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($267.00M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $53.00M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | ($51.85M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $1.82M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($45.07M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($27.75M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($16.60M) | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($386.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($330.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($340.00M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($280.00M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $54.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($124.00M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($88.71M) | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | ($54.86M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($53.44M) | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | ($18.18M) | Mar 5, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $523.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $448.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $340.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $288.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $257.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $159.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $78.48M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $49.65M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $47.22M | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | $14.25M | Mar 5, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($482.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($170.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($306.00M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $438.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($256.00M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $111.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($73.46M) | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | ($43.00M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($25.06M) | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | ($12.94M) | Mar 5, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $6.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $24.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $6.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $26.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $3.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.93M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $3.74M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $5.51M | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | $4.10M | Mar 5, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.15B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.10B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.35B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.59B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $772.29M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $203.11M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $274.93M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $190.49M | Mar 5, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $750.45M | Feb 23, 2022 |
| FY2021 | Dec 31, 2020 | $269.99M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $39.27M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $39.98M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $36.62M | Mar 5, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $631.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $485.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $462.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $657.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $842.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $502.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2019 | $164.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $234.94M | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | ($72.33M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2016 | ($19.99M) | Mar 5, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.49B) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($1.13B) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($849.00M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($542.00M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($275.00M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($328.18M) | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | ($205.33M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($122.83M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($73.23M) | Mar 5, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $222.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $150.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $127.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $206.00M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $148.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $173.42M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $57.94M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $71.06M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $98.43M | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | $65.16M | Mar 5, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $48.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Feb 25, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 23, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 125.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 92.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 75.50M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 72.90M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 70.80M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 65.11M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 45.93M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 44.54M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 4.09M | Mar 5, 2019 |